News
DRRX
1.010
+17.09%
0.147
Weekly Report: what happened at DRRX last week (1111-1115)?
Weekly Report · 6d ago
Based on the provided financial report, the title of the article is: "Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" This title indicates that the report is a quarterly report filed by Durect Corporation with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
Press release · 11/14 22:59
Northland Securities Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 11/14 13:56
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
TipRanks · 11/14 13:06
H.C. Wainwright Remains a Hold on Durect (DRRX)
TipRanks · 11/14 11:27
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 11/14 11:20
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/13 22:10
Durect reports Q3 EPS (14c), consensus (17c)
TipRanks · 11/13 21:05
*Durect: Seeking to Initiate Phase 3 Registrational Trial for Larsucosterol With Topline Results Expected Within Two Years of Initiation >DRRX
Dow Jones · 11/13 21:03
DURECT CORPORATION REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 11/13 21:01
Press Release: DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
Dow Jones · 11/13 21:01
Here are the major earnings after the close today
Seeking Alpha · 11/13 15:00
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/12 23:05
DURECT Q3 2024 Earnings Preview
Seeking Alpha · 11/12 22:35
An Overview of Durect's Earnings
Benzinga · 11/12 19:05
Earnings Preview: Durect
Benzinga · 11/12 18:17
DURECT Corp <DRRX.OQ> expected to post a loss of 17 cents a share - Earnings Preview
Reuters · 11/12 03:47
Weekly Report: what happened at DRRX last week (1104-1108)?
Weekly Report · 11/11 12:27
DURECT CORPORATION TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE
Reuters · 11/06 21:45
Weekly Report: what happened at DRRX last week (1028-1101)?
Weekly Report · 11/04 12:21
More
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.